Aldevron to produce cancer vaccines developed by CureLab Oncology
Aldevron, a biotech company located out of Fargo North Dakota, has decided to produce cancer vaccines created by a CureLab Oncology, based out of Canton MA. CureLab Oncology as a result with be moving most of its operations to Fargo or Grand Forks North Dakota. CureLab CEO Alex Schneider said that the company will be relocating some people but plans to hire much of the staff from local graduates.
The DNA based vaccines developed by CureLab Oncology have so far been tested on animal studies and shown hope in the prospect of suppessing cancers of the lung and breast. the effects when tested showed to inhibit growth in the main tumors, but also slowed down and inhibited metastases. The vaccine has also shown to create memory in the immune system, which allows it to also fight off the affects.
From their Mission Statement:
CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.
Our Lead Product
Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding
gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment,
enhances the anti-cancer effects of other therapies (e.g. chemotherapy),
mitigates chronic inflammation, and stimulates an immune attack on the tumor.
The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
Based on these successful results, we initiated Phase II Clinical Trials outside of the
United States, and are now preparing Phase II Clinical Trials within the US.
Other Related Articles